Respiratory syncytial virus immune globulin intravenous: indications for use. American Academy of Pediatrics Committee on Infectious Diseases, Committee on Fetus and Newborn
Clicks: 469
ID: 120562
1997
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Star Article
30.0
/100
469 views
61 readers
AI Quality Assessment
Not analyzed
Readership in this journal
StarRanked #18 of 581 articles by views in pediatrics
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 581 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Respiratory syncytial virus immune globulin intravenous (RSV-IGIV) has been approved by the Food and Drug Administration for use in the prevention of severe RSV infections in infants and children younger than 24 months with bronchopulmonary dysplasia or a history of premature birth (< or = 35 wee …
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (43 words).
Try re-searching for a better abstract.
| Reference Key |
1997pediatricsrespiratory
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ; |
| Journal | pediatrics |
| Year | 1997 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
National Center for Biotechnology Information
NCBI
NLM
MEDLINE
humans
pubmed abstract
nih
national institutes of health
national library of medicine
Infant
newborn
immunoglobulins
intravenous / therapeutic use*
respiratory syncytial virus infections / prevention & control*
practice guideline
guideline
contraindications
cost-benefit analysis
human / immunology*
respiratory syncytial virus
heart defects
premature
pmid:9093323
bronchopulmonary dysplasia / therapy
congenital
intravenous / economics
|
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.